Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
about
Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosaAntimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and futureLearning from agriculture: understanding low-dose antimicrobials as drivers of resistome expansionCosts of antibiotic resistance - separating trait effects and selective effectsInterplay in the selection of fluoroquinolone resistance and bacterial fitnessPervasive sign epistasis between conjugative plasmids and drug-resistance chromosomal mutationsCompensatory evolution of pbp mutations restores the fitness cost imposed by β-lactam resistance in Streptococcus pneumoniaeThe fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the fieldA trade-off between the fitness cost of functional integrases and long-term stability of integronsResource competition may lead to effective treatment of antibiotic resistant infectionsStrain Dependent Genetic Networks for Antibiotic-Sensitivity in a Bacterial Pathogen with a Large Pan-GenomeBiological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides.Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics.Positive epistasis drives the acquisition of multidrug resistance.High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolatesPlasmidic qnrA3 enhances Escherichia coli fitness in absence of antibiotic exposure.Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations.The cost of antibiotic resistance depends on evolutionary history in Escherichia coli.Directed evolution of aminoglycoside phosphotransferase (3') type IIIa variants that inactivate amikacin but impose significant fitness costs.Induction of prophages by fluoroquinolones in Streptococcus pneumoniae: implications for emergence of resistance in genetically-related clones.Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistanceBottlenecks in the transferability of antibiotic resistance from natural ecosystems to human bacterial pathogens.Interaction of Vaccination and Reduction of Antibiotic Use Drives Unexpected Increase of Pneumococcal Meningitis.Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, BelgiumGlobal fluoroquinolone resistance epidemiology and implictions for clinical use.The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.Antimicrobial Resistance Expressed by Neisseria gonorrhoeae: A Major Global Public Health Problem in the 21st Century.Seasonality of antibiotic-resistant streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy?Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of Pseudomonas aeruginosa Differs by Type III Secretion Genotype.A global view of antibiotic resistance.Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure.Molecular and Proteomic Analysis of Levofloxacin and Metronidazole Resistant Helicobacter pylori.Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulenceRelA Mutant Enterococcus faecium with Multiantibiotic Tolerance Arising in an Immunocompromised Host.Compensation of fitness costs and reversibility of antibiotic resistance mutations.Overview of strategies for overcoming the challenge of antimicrobial resistance.Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.Streptococcus pneumoniae infection: a Canadian perspective.
P2860
Q21144908-8FB6ABD1-3550-4ED2-BCC0-9730049E7608Q26862597-C3C8B9E6-248A-4BE4-8C46-085B14CA13F5Q27002632-A0AFC037-EAD4-4539-A61B-71FC31E718A3Q28082095-B1CD3B75-BDED-4BD4-BD80-D7901955BEC2Q28475870-D9A7A319-F26F-4161-BA78-ACC8CC9EA802Q28476356-D33DA8D0-669A-433B-9E04-5221F6415E33Q28477183-F8101C9A-D557-4A53-AB7F-BE9F6A7F1ABAQ28478903-14EAD772-DCED-4A7F-BF89-167F4763F896Q28485389-4E1B0338-7822-4FD3-93F0-021470F85F2AQ28537662-BBA108FF-4A5B-44B2-9DA4-578255ED6A43Q28553946-583B6149-2C73-4AB6-BC40-6E4464CDE046Q30251593-6070F68E-DAD9-4653-B70B-F055C510D7A8Q33332126-0A1EE34F-EBB5-43F5-B98C-8DD58B5A7358Q33389193-99AF7F18-C92E-4E42-94DB-ACFBD501DD51Q33486486-E5C983B4-2BAD-4A53-9FFA-03B1749956BDQ33798166-3DF7D597-C554-428F-8072-2379543BC313Q34019104-B694F9A5-08EF-4612-9457-EB5B00428ED7Q34049640-A56E8F26-F61C-474E-AAF9-1A072D3B30A5Q34893085-97632CDB-C8D3-4757-99E3-1AD99FB20D24Q35034759-7BE5E2F3-665C-47EF-931F-2DD086CFEB25Q35144206-9A16269D-C2BD-4C7F-B7FE-0977106CAF2DQ35622545-5F58DE4A-571A-4E64-BEC9-FC10710E0C66Q35646654-2D6EE533-2A48-466E-AC65-9A517B9C1BF9Q35716556-30646992-DF31-4820-9AFC-EDEE1B390740Q36154055-0893FD72-C060-4B17-8CE3-60F305C3727FQ36221241-FE560DA4-753A-430F-AB36-9C26AAF6F9FAQ36337074-AF995999-CEBA-4074-8BB2-3EBC0442AB23Q36675409-7DA5D7E6-C14E-48F7-9FF1-31268E56CF65Q37036002-E65ADE07-6E74-4B9C-9193-2F78D352B4ECQ37120857-577F4706-ABAF-468E-8797-A6A22A2DE555Q37306380-E2A3CBB4-3F5D-4569-B9BA-62D8175AE2EAQ37340607-93C3667D-6BCD-417A-BAB8-2852D40D62C4Q37379658-49F4EA54-D7A8-45FE-AD51-01165D9E6262Q37505662-9164D25D-BDF9-4A0C-9749-4A74D516E915Q37545098-98C55C6B-C233-4B1E-93E0-1BD31505166DQ37556629-571A980F-DE87-4C54-8D4A-2514B882FD16Q37696851-24886238-039B-46F3-8AD2-F749136532F5Q37960104-8A94C73D-5569-4F3F-9B20-99D18BD87745Q37998398-B8B71081-37AC-41D2-8356-CB110E058716Q38131534-1D4BD280-235C-4967-9EBA-17E678A26C6C
P2860
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@ast
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@en
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@nl
type
label
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@ast
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@en
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@nl
prefLabel
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@ast
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@en
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
@nl
P2860
P356
P1476
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae
@en
P2093
Bruce R Levin
Lesley McGee
P2860
P304
P356
10.1128/AAC.01161-06
P407
P577
2006-11-20T00:00:00Z